US Stock MarketDetailed Quotes
ADMA ADMA Biologics
- 18.090
- +0.440+2.49%
Close Sep 13 16:00 ET
- 18.000
- -0.090-0.50%
Post 20:01 ET
4.22BMarket Cap129.21P/E (TTM)
18.425High17.850Low4.24MVolume17.850Open17.650Pre Close76.87MTurnover1.85%Turnover RatioLossP/E (Static)233.08MShares19.34052wk High22.39P/B4.14BFloat Cap3.06052wk Low--Dividend TTM228.84MShs Float19.340Historical High--Div YieldTTM3.26%Amplitude1.010Historical Low18.135Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
ADMA Biologics Stock Forum
Looking for 15 before jumping back in
We are growing much more confident in identifying growing companies.
The problem now is, when to take profit? When to re-open position?
For example, we rode $ADMA Biologics (ADMA.US)$ from before earnings to $18 and closed out. Except they will easily be more successful in the future - and have continued running. The balance when it is overbought to the momentum of the trend is tough!!
Another example is $Nanoviricides (NNVC.US)$ : we rode them to their 52-week high ...
ADMA Biologics, Inc. (Nasdaq: ADMA), a commercial biopharmaceutical company specializing in manufacturing and marketing specialty biologics, has announced its financial results for the second quarter of 2024. The company reported growth in revenue, net income, and adjusted EBITDA, reflecting the robustness of its operations a...
Validating! ADMA was one of my very first picks when I started my journey in stocks. Seeing it take off and succeed based on solid fundamentals is a great boost to my self-confidence in my lebragging.
Hopefully, that doesn't sound too braggy. I'm not anything but a shitty new trader. It's important to recognize success when I have it, though. If for no other reason than to keep morale up during shitty downside weeks.
2Q 2024 Total Revenue of $107.2 Million, a 78% Increase Y-o-Y
2Q 2024 GAAP Net Income of $32.1 Million, a $38.4 Million Increase Y-o-Y
2Q 2024 Adjusted EBITDA(1) of $44.5 Million, a Nearly 600% Increase Y-o-Y
Commercial Scale Production of ADMA’s Innovative Biologics Manufacturing Process Supports a Potential Yield Enhancement of Approximately 20% from Same Start...
The tech sector, specifically semiconductors and Ai/crypto companies, aren't going anywhere. NVDA isn't going to just shrug their shoulders and give up tomorrow.
So long as you have researched and relied on financials, I think it will all come back and probably stronger than ever.
In the meantime, I've added to a couple of "defense" stocks:
$ADMA Biologics (ADMA.US)$ : 58.8% U...
No comment yet